HUP9903584A2 - Kinolinszármazékok NK3 antagonistákként alkalmazható sói - Google Patents

Kinolinszármazékok NK3 antagonistákként alkalmazható sói

Info

Publication number
HUP9903584A2
HUP9903584A2 HU9903584A HUP9903584A HUP9903584A2 HU P9903584 A2 HUP9903584 A2 HU P9903584A2 HU 9903584 A HU9903584 A HU 9903584A HU P9903584 A HUP9903584 A HU P9903584A HU P9903584 A2 HUP9903584 A2 HU P9903584A2
Authority
HU
Hungary
Prior art keywords
alkyl
optionally substituted
ring
aminoalkyl
alkoxycarbonyl
Prior art date
Application number
HU9903584A
Other languages
English (en)
Inventor
Carlo Farina
Giuseppe Arnaldo Maria Giardina
Mario Grugni
Luca Francesco Raveglia
Original Assignee
Smithkline Beecham S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham S.P.A. filed Critical Smithkline Beecham S.P.A.
Publication of HUP9903584A2 publication Critical patent/HUP9903584A2/hu
Publication of HUP9903584A3 publication Critical patent/HUP9903584A3/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C07D215/52Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

A találmány egy (I) általánős képletű vegyületnek -, amelynekképletében Ar adőtt esetben szűbsztitűált fenil-, naftil- vagy ciklőalkadienil-vagy heterőciklűsős csőpőrt; R alkil-, ciklőalkil-, ciklőalkil-alkil-, adőtt esetben szűbsztitűáltfenil-, fenil-alkil- vagy heterőarőmás csőpőrt, hidrőxi-alkil-, aminő-alkil-, alkil-aminő-alkil-, dialkil-aminő-alkil-, acil-aminő-alkil-,alkőxi-alkil-, alkil-karbőnil-, karbőxi-, alkőxi-karbőnil-, alkőxi-karbőnil-alkil-, karbamőil-, alkil-aminő-karbőnil-, dialkil-aminő-karbőnil-, halőgén-alkil-csőpőrt vagy az Ar csőpőrtra ciklizált -(CH2)p- csőpőrt, amelyben p értéke 2 vagy 3; R1 és R2 hidrőgénatőm, alkilcsőpőrt vagy együtt -(CH2)n-csőpőrt,amelyben n értéke 3, 4 vagy 5; vagy R1 és R együtt -(CH2)q-csőpőrt, amelyben q értéke 2, 3, 4 vagy 5; R3 és R4 hidrőgénatőm, alkil-, alkenil-, aril-, alkőxi-,hidrőxicsőpőrt, halőgénatőm, nitrő-, cianő-, karbőxi-, karbőxamidő-,szűlfőnamidő-, alkőxi-karbőnil-, triflűőr-metil-, acil-őxi-,ftálimidő-, aminő-, mőnő- vagy dialkil-aminő-, -O(CH2)r -NT2 csőpőrt,amelyben r értéke 2, 3 vagy 4, és T hidrőgénatőm, alkilcsőpőrt vagy a szőmszédős nitrőgénatőmal együttegy csőpőrtőt képez, amelyben V és V1 hidrőgénatőm vagy őxigénatőm, ésű értéke 0, 1 vagy 2; -O(CH2)s-OW2 csőpőrt, amelyben s értéke 2, 3vagy 4, és W hidrőgénatőm vagy alkilcsőpőrt; hidrőxi-alkil-, aminő-alkil-, mőnő- vagy dialkil-aminő-alkil-, acil-aminő-, alkil-szűlfőnil-aminő-, aminő-acil-aminő-csőpőrt, mőnő- vagy dialkil-aminő-acil-aminő-csőpőrt; és egyidejűleg legfeljebb négy R3 szűbsztitűens lehet akinőlinmagőn; vagy R4 az arőmás R5 csőpőrtra ciklizálva -(CH2)t- csőpőrt, amelyben tértéke 1, 2 vagy 3; R5 alkil-, ciklőalkil-, ciklőalkil-alkil-csőpőrt vagy adőtt esetbenszűbsztitűált heterőarilcőspőrt; X őxigén-, kénatőm vagy =N-C=N csőpőrt - egy sójára (a tővábbiakban(találmány szeirnti só) vagy egy ilyen sónak egy szőlvátjáravőnatkőzik, ahől a só egy aniőnős főrmában lévő (I) általánős képletűvegyületből és egy sóképző katiőnból áll. A találmány szerintivegyületek NK3 receptőr antagőnista hatással rendelkeznek, ígyfelhasználhatók - egyebek mellett - pűlmőnalis, közpőnti idegrendszeriés neűrődegeneratív rendellenességek kezelésére. A találmány kiterjeda vegyületek gyógyászati felhasználására, előállítási eljárásaikra,valamint a vegyületeket hatóanyagként tartalmazógyógyszerkészítményekre és ezek előállítási eljárásaira is. ŕ
HU9903584A 1995-11-24 1996-11-22 Salts of quinoline derivatives as nk3 antagonists HUP9903584A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9524137.8A GB9524137D0 (en) 1995-11-24 1995-11-24 Novel compounds
PCT/EP1996/005210 WO1997019928A1 (en) 1995-11-24 1996-11-22 Salts of quinoline derivatives as nk3 antagonists

Publications (2)

Publication Number Publication Date
HUP9903584A2 true HUP9903584A2 (hu) 2000-02-28
HUP9903584A3 HUP9903584A3 (en) 2001-10-29

Family

ID=10784449

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9903584A HUP9903584A3 (en) 1995-11-24 1996-11-22 Salts of quinoline derivatives as nk3 antagonists

Country Status (23)

Country Link
US (3) US6355654B1 (hu)
EP (1) EP0876348B1 (hu)
JP (1) JP4377454B2 (hu)
KR (1) KR19990071599A (hu)
CN (1) CN1207728A (hu)
AR (1) AR004970A1 (hu)
AT (1) ATE233243T1 (hu)
AU (1) AU722451B2 (hu)
BR (1) BR9611729A (hu)
CA (1) CA2238312A1 (hu)
CZ (1) CZ158198A3 (hu)
DE (1) DE69626416T2 (hu)
ES (1) ES2192621T3 (hu)
GB (1) GB9524137D0 (hu)
HU (1) HUP9903584A3 (hu)
IL (1) IL124352A0 (hu)
MX (1) MX9804106A (hu)
NO (1) NO310866B1 (hu)
NZ (1) NZ323389A (hu)
PL (1) PL326927A1 (hu)
TR (1) TR199800925T2 (hu)
WO (1) WO1997019928A1 (hu)
ZA (1) ZA969812B (hu)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9825554D0 (en) 1998-11-20 1999-01-13 Smithkline Beecham Spa Novel Compounds
US7037922B1 (en) 2000-03-10 2006-05-02 Neurogen Corporation Aryl fused 2,4-disubstituted pyridines: NK3 receptor ligands
AU4038000A (en) 1999-03-29 2000-10-16 Neurogen Corporation 4-substituted quinoline derivatives as gaba receptor ligands
WO2000064877A1 (en) 1999-04-26 2000-11-02 Neurogen Corporation 2-aminoquinolinecarboxamides: neurokinin receptor ligands
JP2008542367A (ja) * 2005-06-03 2008-11-27 アストラゼネカ・アクチエボラーグ Nk−3アンタゴニストとしてのキノリン誘導体
GB0515580D0 (en) 2005-07-29 2005-09-07 Merck Sharp & Dohme Therapeutic compounds
WO2007016609A2 (en) * 2005-08-02 2007-02-08 Smithkline Beecham Corporation Method for the synthesis of quinoliνe derivatives
WO2007018469A1 (en) * 2005-08-11 2007-02-15 Astrazeneca Ab Oxopyridyl quinoline amides as nk3 receptor modulators
AR057130A1 (es) * 2005-09-21 2007-11-14 Astrazeneca Ab Quinolinas de alquilsulfoxido y una composicion farmaceutica
EP1940795A1 (en) * 2005-09-21 2008-07-09 AstraZeneca AB N-oxo-heterocycle and n-oxo-alkyl quinoline-4-carboxamides as nk-3 receptor ligands
TW201018662A (en) 2005-12-12 2010-05-16 Astrazeneca Ab Alkylsulphonamide quinolines
CN101410392A (zh) * 2006-01-27 2009-04-15 阿斯利康(瑞典)有限公司 酰胺取代的喹啉类化合物
FR2979173B1 (fr) * 2011-08-19 2013-08-16 St Microelectronics Grenoble 2 Commutateur analogique basse tension
WO2013066736A1 (en) * 2011-11-03 2013-05-10 Merck Sharp & Dohme Corp. QUINOLINE CARBOXAMIDE AND QUINOLINE CARBONITRILE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE
EP2986293A1 (en) 2013-04-19 2016-02-24 Astrazeneca AB A nk3 receptor antagonist compound (nk3ra) for use in a method for the treatment of polycystic ovary syndrome (pcos)
WO2017072629A1 (en) 2015-10-29 2017-05-04 Cadila Healthcare Limited Pharmaceutical combination of nk3 receptor antagonist and biguanides

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0804419B1 (en) * 1994-05-27 2003-08-06 SmithKline Beecham Farmaceutici S.p.A. Quinoline derivatives as tachykinin nk 3 receptor antagonists
IT1270615B (it) * 1994-07-14 1997-05-07 Smithkline Beecham Farma Uso di derivati di chinolina

Also Published As

Publication number Publication date
NO982332L (no) 1998-05-22
NZ323389A (en) 2000-02-28
BR9611729A (pt) 1999-04-06
KR19990071599A (ko) 1999-09-27
DE69626416D1 (de) 2003-04-03
EP0876348B1 (en) 2003-02-26
JP4377454B2 (ja) 2009-12-02
GB9524137D0 (en) 1996-01-24
NO982332D0 (no) 1998-05-22
ES2192621T3 (es) 2003-10-16
CA2238312A1 (en) 1997-06-05
AU722451B2 (en) 2000-08-03
US20020156097A1 (en) 2002-10-24
CZ158198A3 (cs) 1998-10-14
CN1207728A (zh) 1999-02-10
DE69626416T2 (de) 2003-12-24
ZA969812B (en) 1998-05-22
JP2000500770A (ja) 2000-01-25
PL326927A1 (en) 1998-11-09
ATE233243T1 (de) 2003-03-15
IL124352A0 (en) 1998-12-06
HUP9903584A3 (en) 2001-10-29
TR199800925T2 (xx) 2001-05-21
NO310866B1 (no) 2001-09-10
US6355654B1 (en) 2002-03-12
US20020077335A1 (en) 2002-06-20
WO1997019928A1 (en) 1997-06-05
AR004970A1 (es) 1999-04-07
MX9804106A (es) 1998-09-30
US6432977B1 (en) 2002-08-13
EP0876348A1 (en) 1998-11-11
AU1031997A (en) 1997-06-19

Similar Documents

Publication Publication Date Title
HUP9903584A2 (hu) Kinolinszármazékok NK3 antagonistákként alkalmazható sói
CA2238171A1 (en) Quinoline derivatives as nk3 antagonists
NO304946B1 (no) Xantinderivat samt dets anvendelse
HK1008918A1 (en) N-substituted heterocycle derivatives their preparation compositions containing them
MX9804108A (es) Derivados de quinolina-4-carboxamida, su preparacion y uso como antagonistas receptores de neuroquinina 3 (nk-3)- y neuroquinina 2 (kn-2).
HU9402911D0 (en) Perhydroisoindole derivatives as p substance antagonists
MA27433A1 (fr) Derives de la quinolyl propyl piperidine et leur utilisation en tant qu'agents antimicrobiens
HU9402459D0 (en) Pyrazolitriazines with interleukin-i and tumor necrosis factor inhibitors
PL324795A1 (en) Application of adamantane derivatives in treating internal ear diseases
EP1176958A4 (en) NEW CATECHOLS USED AS ANTIMICROBIAL AGENTS
AU1227795A (en) Cosmetic or pharmaceutical compositions consisting of liposomes
AU1556997A (en) Chinoline and benzimidazole derivatives as bradykinin agonists
ATE214067T1 (de) Pyrido (2,3-b) pyrazinderivate
IE892596L (en) Arylalkyl-amines and -amides having anticonvulsant and¹neuroprotective properties
TW349864B (en) Use of N-(pyridinyl)-1H-indol-a-amines for the preparation of a medicament for the treatment of obsessive-compulsive disorders
NO953913D0 (no) Perhydroisoindolderivater, deres fremstilling samt farmasöytiske preparater inneholdende derivatene
HUT34479A (en) Process for preparing imidazo/4,5-c/quinolines
IT1276170B1 (it) Derivati chinolinici
IT1307331B1 (it) Derivati chinolinici
HUP9903427A2 (hu) Kinolinszármazékok, eljárás előállításukra, valamint a vegyületeket tartalmazó gyógyszerkészítmények
NZ336969A (en) Substituted 4-aminoalkoxy-1H-benzimidazole derivatives useful as dopamine autoreceptor (D2) agonists
IT1293558B1 (it) Derivati chinolinici
DE69403896D1 (de) 4-amino-2-(hetero)aryl-butanamide verwenbar als 5-ht1a-antagonisten
HUT60742A (en) Method for producing imidqzo-benzodiazepine-2-(1h)-one derivatives and pharmaceutical preparatives containing them
IT1276171B1 (it) Derivati chinolinici